Profile picture

Professor Gerald Watts

University of Western Australia, Perth (Australia)
Membership: FESC Member
Follow
Biography
GERALD F WATTS, DSc DM PhD FRCP FRACP FCSANZ. Gerald Watts trained at Imperial & King’s College, London University, and was a scholar at Wolfson College, Oxford University. He is a senior consultant physician, specializing in the rapidly developing field of cardio-metabolic medicine, and current chair of the Familial Hypercholesterolemia Australasia Network. He leads the Cardio-metabolic Service in the Departments of Cardiology and Internal Medicine at Royal Perth Hospital and is Winthrop Professor of Cardio-metabolic Medicine in the University of Western Australia. Research interests include fundamental and applied aspects of lipid disorders and cardiovascular prevention, and improving healthcare delivery for patients with high risk dyslipidemias, in particular familial hypercholesterolaemia and hyperchylomicronaemia. He has supervised several Masters, MD and PhD students and post-doctoral research fellows, and holds several research grants, with multiple collaborations.
Logo ESC

Contributor content

A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension
Presentation
A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension
A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome
Presentation
A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome
RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL cholesterol concentrations: first human results with ARO-ANG3
Presentation
RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL cholesterol concentrations: first human results with ARO-ANG3
RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia
Presentation
RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia
Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism: the FLOREY stable isotope study
Presentation
Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism: the FLOREY stable isotope study
RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia
Presentation
RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

ESC 365 is supported by